LOS ANGELES, CA / ACCESSWIRE / August 2, 2016 / Lundin Law PC (the "Firm") announces that a class action lawsuit was filed against Immunomedics Inc. ("Immunomedics" or the "Company") (Nasdaq: IMMU) concerning possible violations of federal securities laws between April 20, 2016 and June 2, 2016 (the "Class Period"). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 8, 2016 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
The complaint alleges that during the Class Period, Immunomedics issued false and misleading statements to investors and/or failed to disclose: that the Company's abstract for antibody-drug IMMU-132 submitted to the American Society of Clinical Oncology (ASCO) for presentation at their 2016 Annual Meeting contained previously disclosed results from a mid-stage study; that Immunomedics misrepresented to ASCO that the abstract contained only updated and previously undisclosed data; and that as a result of this ASCO removed the IMMU-132 presentation from the 2016 ASCO Annual Meeting schedule. When this news was announced, shares of Immunomedics fell in value, causing investors harm.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact:
Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/
SOURCE: Lundin Law PC
ReleaseID: 443103
